Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 08, 2022
Share
Yung Zip Chemical Ind. Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 108.15 million compared to TWD 107.37 million a year ago. Net income was TWD 5.29 million compared to net loss of TWD 3.09 million a year ago. Basic earnings per share from continuing operations was TWD 0.12 compared to basic loss per share from continuing operations of TWD 0.07 a year ago. Diluted earnings per share from continuing operations was TWD 0.12 compared to diluted loss per share from continuing operations of TWD 0.07 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.